Summary

Ecnoglutide (also known as XW003) is a long-acting, biased GLP-1 receptor agonist developed by Sciwind Pharmaceuticals. Unlike conventional GLP-1 agonists, ecnoglutide is designed to preferentially activate G-protein signalling pathways over β-arrestin recruitment, which may offer improved efficacy and tolerability. Phase 3 trial results published in 2025 demonstrated significant weight loss in adults with overweight or obesity. It is not currently licensed in the UK.

Mechanism

Ecnoglutide is a biased GLP-1 receptor agonist. It preferentially activates the G-protein signalling pathway (cAMP/PKA) at the GLP-1 receptor while showing reduced β-arrestin recruitment compared to unbiased agonists like semaglutide. This biased signalling profile is hypothesised to sustain receptor activity (less desensitisation/internalisation) and may reduce gastrointestinal side effects. The net effect is enhanced insulin secretion in a glucose-dependent manner, suppression of glucagon, delayed gastric emptying, and increased satiety — consistent with GLP-1 receptor pharmacology.

Evidence base

A Phase 3 randomised, double-blind, placebo-controlled, multicentre trial published in The Lancet Diabetes & Endocrinology (2025) demonstrated statistically significant weight loss with ecnoglutide in adults with overweight or obesity. This is the first Phase 3 readout for the compound. Evidence grade: Moderate. The trial supports ecnoglutide's efficacy as a GLP-1 RA, but head-to-head comparisons with approved agents and long-term cardiovascular outcomes data are not yet available.

Protocols

In Phase 3 trials, ecnoglutide was administered as a once-weekly subcutaneous injection with a dose-titration schedule. Specific dose levels have not been prominently disclosed in publicly available topline results. As an investigational compound, no approved dosing guidelines exist.

Work out the draw →

Ecnoglutide is not licensed by the MHRA and is not approved as a medicine in the UK. It is an investigational peptide in the grey area — legal for research purposes but not available as an approved therapeutic. The MHRA has not evaluated ecnoglutide for safety, quality, or efficacy.

References

  1. Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Diabetes & Endocrinology, 2025. DOI: 10.1016/S2213-8587(25)00141-X
  2. ClinicalTrials.gov search results for ecnoglutide. Available at: https://clinicaltrials.gov/search?term=ecnoglutide